The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria (CSU), a condition that causes painful hives that often don't respond to ...

Sanofi has added to its vaccine pipeline with an agreement to acquire Austria's Origimm Biotechnology and its vaccine-based immunotherapy for people with acne. The French group said that ORI-001 ...